And to the right, you can see our revenue and EBITDA, with adjusted EBIT margin development over time. During Q3, we exceeded the 7 billion milestone as our revenue amounted to 7,082,000,000 Swedish in rolling 12 months.
And during the same period, the adjusted EBIT margin was 4.9%. So, we are at the upper end of the financial targets, within the corridor of 3 to 5%. To the left, you can see a breakdown of our sales. In Q3. We had a growth of 8.9% in the quarter, and the growth was driven by strong sales of 13.6%, while OTC and traded goods grew by 6.3%. And as Pär mentioned, we have expanded the capacity in Rx, and we see a continued increase in the demand to buy prescription medicines online. To the right, you see a breakdown of the gross margin development in Q3. And we had a stable gross margin in Q3 of over 27.2%. We had a strong operating margin in Q3. We're very happy with that. And we managed to offset the cost increases in Varberg related to the production launch there and the scale-up of production with efficiencies elsewhere in our logistics and continued good cost control. The adjusted EBIT margin in Q3 was 5%.
We didn't have any items affecting comparability in the quarter.
To the right, we have a breakdown of our operating cost as a percentage of our sales. As you can see, we increased the depreciation percentage somewhat in Q3 as we started to depreciate a smaller part of the fixed assets related to Varberg. However, the majority of the fixed assets in Varberg will start to depreciate in Q4. So we've not seen that effect in Q3, but we expect that in Q4.
We had strong operating cash flow in Q3.
We had an operating cash flow of 109 million SEK, up from 55 million a year ago. The operating cash flow was supported or driven by increased earnings, as well as changes in the working capital. We had CapEx of 68 million in Q3, and that's related to the Varberg expansion or the launching of production in Varberg. We have now completed the CapEx related to Varberg, a total investment of 380 million.
You can also note that part of the 68 million in CapEx in Q3 will be paid in Q4. As mentioned, we expect full depreciation of the assets in the current quarter. To the right, you see our net working capital development. We had an inventory turnover rate of 7.6% at the end of September. And that was affected by the build-up of inventory in Varberg. As we scale up production, we can also begin to optimize the inventory levels, and we expect to balance the inventory between the different warehouses. And we expect long term to have a stable operating cash flow model and a high inventory turnover rate.
We had a continuous solid return on capital employed of 34.4%, which is shown to the left here on the slide. are. The earnings, by and large, compensated for the increase in net assets or in capital employed.
We had a solid net cash position of 98 million Swedish kronor at the end of September. The increase in cash position was due to the strong operating cash flow and partly affected by changes in net working capital. Net working capital will vary from quarter to quarter. But over time, we expect to have stable and high operating cash flow generation. Yes. Finally, let's look at the year to date numbers, growth and profitability.
We had on the left. You see our growth year to date, September, which was at 11.2%, driven also by strong Rx growth. September.
To the right, you can see that we managed to increase the adjusted EBIT margin by late September from 4.6% to 5.2%. And the adjustments year to date relate to the revaluation of shareholding in Q2, specifically the revaluation of shareholding in Apomera AB that was communicated in the Q2 report, and the adjustment was 6.2 million.
The Ebit for January to September was 5.1%.